Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02870036 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 243 | Haihe Biopharma Co., Ltd.INDUSTRY |
| 1 |
| Jul 14, 2017 |
| clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT03166878 | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02752360 | Biodegradable Stenting Anastomoses Versus Double-layer Hand Sutures for Reconstruction in Intestinal Anastomosis | unknown | Phase 1 | 288 | Beijing Friendship HospitalOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | unknown | Phase 1 / Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT03114670 | Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | unknown | Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01926821 | Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy | unknown | Phase 1 | 200 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT03164837 | 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT03146533 | CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 20 | Shenzhen Second People's HospitalOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03154775 | Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | unknown | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | May 16, 2017 | clinicaltrials |
| NCT03151447 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer | unknown | Phase 1 | 18 | Fudan UniversityOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | unknown | Phase 1 | 20 | University of NottinghamOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02739529 | Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer | unknown | Phase 1 | 18 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 1, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02349724 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | unknown | Phase 1 | 75 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03121625 | CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 25, 2017 | clinicaltrials |
| NCT03124498 | A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA | unknown | Phase 1 / Phase 2 | 55 | Chuan An Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03118180 | CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02493829 | B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) | unknown | Phase 1 | 10 | King's College LondonOTHER | 0 | Apr 13, 2017 | clinicaltrials |
| NCT00184015 | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | unknown | Phase 1 / Phase 2 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02496013 | Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB | unknown | Phase 1 | 70 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT03101709 | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | unknown | Phase 1 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 5, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT03086954 | Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma(EECPL) | unknown | Phase 1 | 24 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Mar 22, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02912754 | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | unknown | Phase 1 / Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02721407 | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients(MendCART) | unknown | Phase 1 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT03076957 | A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj. | unknown | Phase 1 / Phase 2 | 24 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03026881 | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | unknown | Phase 1 | 24 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 7, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT03051269 | Calcium Electroporation for Head and Neck Cancer | unknown | Phase 1 | 6 | Rigshospitalet, DenmarkOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02762474 | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | unknown | Phase 1 / Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02396108 | Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer | unknown | Phase 1 / Phase 2 | 55 | National University Hospital, SingaporeOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00049244 | BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer | unknown | Phase 1 | — | R-PharmINDUSTRY | 1 | Jan 30, 2017 | clinicaltrials |
| NCT03029533 | Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer | unknown | Phase 1 | 44 | Daewoong Pharmaceutical Co. LTD.INDUSTRY | 0 | Jan 24, 2017 | clinicaltrials |
| NCT02446795 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial(QUASAR) | unknown | Phase 1 / Phase 2 | 104 | Consorzio OncotechOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT01304797 | Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer | unknown | Phase 1 | 75 | Merrimack PharmaceuticalsINDUSTRY | 1 | Jan 6, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jul 19, 2017source: clinicaltrials